Drug search by name

Sinemet 25-250 and Melanoma

Result of checking the interaction of drug Sinemet 25-250 and disease Melanoma for safety when used together.

Check result:

Sinemet 25-250 <> Melanoma

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

The use of levodopa is considered by manufacturers to be contraindicated in patients with a history of melanoma or in patients with suspicious, undiagnosed skin lesions. Levodopa reportedly may activate malignant melanoma, although some investigators have found a causal relationship to be tenuous.

References:

Abramson DH, Rubenfeld MR "Choroidal melanoma and levodopa" JAMA 252 (1984): 1011-2
Sober AJ, Wick MM "Levodopa therapy and malignant melanoma." JAMA 240 (1978): 554-5
Haider SA, Thaller VT "Lid melanoma and parkinsonism." Br J Ophthalmol 76 (1992): 246-7
Fermaglich J, Delaney P "Parkinson's disease, melanoma, and levodopa." J Neurol 215 (1977): 221-4
Fermaglich J, Delaney P "Levodopa and melanoma" JAMA 241 (1979): 883-4
Weiner WJ, Singer C, Sanchez-Ramos JR, Goldenberg JN "Levodopa, melanoma, and Parkinson's disease." Neurology 43 (1993): 674-7
"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals, Wilmington, DE.
Bernstein JE, Medenica M, Soltani K, Solomon A, Lorincz AL "Levodopa administration and multiple primary cutaneous melanomas." Arch Dermatol 116 (1980): 1041-44
Van Rens GH, De Jong PT, Demols EE, Brihaye-Van Geertruyden MF "Uveal malignant melanoma and levodopa therapy in Parkinson's disease." Ophthalmology 89 (1982): 1464-6
Kochar AS "Development of malignant melanoma after levodopa therapy for Parkinson's disease. Report of a case and review of the literature." Am J Med 79 (1985): 119-21
Rosin MA, Braun M, 3d Braun M "Malignant melanoma and levodopa." Cutis 33 (1984): 572-4
Gurney H, Coates A, Kefford R "The use of L-dopa and carbidopa in metastatic malignant melanoma." J Invest Dermatol 96 (1991): 85-7
Robinson E, Wajsbort J, Hirshowitz B "Levodopa and malignant melanoma." Arch Pathol 95 (1973): 213
"Product Information. Sinemet CR (carbidopa-levodopa)." Dupont Pharmaceuticals, Wilmington, DE.